Can-Fite BioPharma Ltd. focuses on small molecule therapies targeting the A3 adenosine receptor, with lead programs in Phase III trials for inflammatory and cancer indications. Despite clinical milestones such as positive pancreatic cancer Phase IIa data and expanded patent allowances for Namodenoson, the company’s revenues fell nearly 40% in 2025 due to milestone timing and distribution patterns. Operating losses widened 22%, driven by higher research expenses supporting late-stage trials, while liquidity remains constrained but sufficient for twelve months backed by recent financing. The business model relies heavily on out-licensing deals, royalties, and capital raises, leaving upside tied closely to clinical trial outcomes and regulatory approvals.